The vaccine primes neoantigen-specific T cells; CD8+ T cells kill tumor cells presenting neoantigen peptides on MHC class I (perforin/granzyme). HLA-DPB1 is only an HLA class II presenter for helper T-cell priming and is not itself a killing target.